Prostate International最新文献

{"title":"Combination of multiparametric magnetic resonance imaging and transperineal template-guided mapping prostate biopsy to determine potential candidates for focal therapy","authors":"Young Hyo Choi ,&nbsp;Chung Un Lee ,&nbsp;Wan Song ,&nbsp;Byong Chang Jeong ,&nbsp;Seong Il Seo ,&nbsp;Seong Soo Jeon ,&nbsp;Hyun Moo Lee ,&nbsp;Hwang Gyun Jeon ,&nbsp;Seung-Ju Lee","doi":"10.1016/j.prnil.2022.12.003","DOIUrl":"10.1016/j.prnil.2022.12.003","url":null,"abstract":"<div><h3>Background</h3><p>We assessed the ability of the combination of multiparametric magnetic resonance imaging (mpMRI) and transperineal template-guided mapping biopsy (TTMB) to determine the eligibility for focal therapy (FT) (hemiablation) in men and compared it with that of histology from radical prostatectomy (RP) specimens.</p></div><div><h3>Materials and methods</h3><p>In this study, 120 men who underwent mpMRI, TTMB, and RP in a single tertiary center from May 2017 to June 2021 were analyzed. The criteria of hemiablation eligibility were unilateral low-to intermediate-risk prostate cancer (limited to a maximum of International Society of Urological Pathology (ISUP) grade group 3 and prostate-specific antigen (PSA) &lt;20 ng/mL) and clinical stage ≤T2. Evidence of non-organ-confined disease or contralateral Prostate Imaging Reporting and Data System (PI-RADS) v2 score ≥4 on mpMRI was classified as ineligible for hemiablation. Clinically significant cancer at RP was defined as any of the following: (1) ISUP grade group 1 with tumor volume ≥1.3 mL; (2) ISUP grade group ≥2; or (3) the presence of advanced stage (≥pT3).</p></div><div><h3>Results</h3><p>Of the 120 men, data of 52 men who met the selection criteria for hemiablation were compared with final RP findings. Of these 52 men, 42 (80.7%) could be considered suitable for hemiablation on RP. The sensitivity, specificity, and accuracy of mpMRI and TTMB in predicting FT eligibility were 80.7%, 85.1%, and 82.5%, respectively. The rate of undetected contralateral significant cancer was 10 (19.2%) on mpMRI and TTMB. Six had bilateral significant cancer and four had small volumes of ISUP grade group ≥2.</p></div><div><h3>Conclusions</h3><p>The combination of mpMRI and TTMB substantially improves the prediction of potential candidates for hemiablation based on consensus recommendations. Improved selection criteria and further investigative tools are required to improve patient selection for hemiablation.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 2","pages":"Pages 100-106"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/5f/main.PMC10318325.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How many cores should be taken from each region of interest when performing a targeted transrectal prostate biopsy?","authors":"Serhat Cetin ,&nbsp;Arif Huseyinli ,&nbsp;Murat Yavuz Koparal ,&nbsp;Ender Cem Bulut ,&nbsp;Murat Ucar ,&nbsp;Ipek I. Gonul ,&nbsp;Sinan Sozen","doi":"10.1016/j.prnil.2023.01.003","DOIUrl":"10.1016/j.prnil.2023.01.003","url":null,"abstract":"<div><h3>Background</h3><p>The number of core biopsies required per region of interest (ROI) is controversial, as is the localization of the core to be taken from a lesion. This study aimed to determine the ideal biopsy core number and location in a multiparametric magnetic resonance imaging guided targeted prostate biopsy (TPB), without reducing the clinically significant prostate cancer (csPC) detection rate.</p></div><div><h3>Materials and methods</h3><p>Data of patients who had PI-RADS ≥3 lesions on multiparametric magnetic resonance imaging and underwent a TPB in our clinic between October 2020 and January 2022 were reviewed, retrospectively. The first and second cores were taken from the central part of the ROI, whereas the third and fourth cores were taken from the right and left peripheries of the ROI. We compared the csPC detection success of single-, 2-, 3-, and 4-core samplings.</p></div><div><h3>Results</h3><p>Software-based transrectal TPB was performed on 251 ROIs in a total of 167 patients. Internal Society of Urological Pathology Grade Group ≥2 cancer was detected in at least one core in 64 (25.4%) lesions. Moreover, csPC was detected in 42 (65.6%) ROIs in first-core biopsies; in 59 (92.2%) ROIs in first- and second-core biopsies; in 62 (96.9%) ROIs in first-, second-, and third-core biopsies; and in 64 (100%) ROIs in first-, second-, third-, and fourth-core biopsies. Using McNemar's test for comparison, a significant difference was found in terms of csPC detection success between performing first-core and second-core biopsies (65.6 – 92.2%, <em>p</em> &lt; 0.001); by contrast, no significant difference was observed in csPC detection success between 2-core and 3-core biopsies (92.2% - 96.9%, <em>p</em> = 0.24). Furthermore, no significant difference existed between performing second-core and fourth-core biopsies in terms of csPC detection success (92.2%–100%, <em>p</em> = 0.07).</p></div><div><h3>Conclusion</h3><p>We concluded that taking 2-core biopsies from the center of each ROIs during a transrectal TPB is sufficient for diagnosing csPC.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 2","pages":"Pages 122-126"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/94/main.PMC10318326.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10180971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways","authors":"Yunlim Kim ,&nbsp;Sangjun Yoo ,&nbsp;Bumjin Lim ,&nbsp;Jun Hyuk Hong ,&nbsp;Cheol Kwak ,&nbsp;Dalsan You ,&nbsp;Jung Jin Hwang ,&nbsp;Choung-Soo Kim","doi":"10.1016/j.prnil.2022.11.003","DOIUrl":"10.1016/j.prnil.2022.11.003","url":null,"abstract":"<div><h3>Background</h3><p>Metformin and phenformin, biguanide derivatives that are widely used to treat type 2 diabetes mellitus, have recently been shown to exert potential anticancer effects in prostate cancer. This study compared the antiprostate cancer effects of the novel biguanide derivative IM176 with those of metformin and phenformin.</p></div><div><h3>Methods</h3><p>Prostate cancer cell lines and patient-derived castration-resistant prostate cancer (CRPC) cells were treated with IMI76, metformin, and phenformin. The effects of these agents on cell viability, annexin V-FITC apoptosis, mammalian target of rapamycin inhibition, protein expression and phosphorylation, and gene expression were evaluated.</p></div><div><h3>Results</h3><p>IM176 dose dependently reduced the viability of all prostate cancer cell lines tested, with IC₅₀s (LNCaP: 18.5 μM; 22Rv1: 36.8 μM) lower than those of metformin and phenformin. IM176 activated AMP-activated protein kinase, inhibiting mammalian target of rapamycin and reducing the phosphorylation of p70S6K1 and S6. IM176 inhibited the expression of androgen receptor, the androgen receptor splice variant 7, and prostate-specific antigen in LNCaP and 22Rv1 cells. IM176 increased caspase-3 cleavage and annexin V-positive/propidium iodide–positive cells, which indicated apoptosis. Moreover, IM176 reduced viability, with low IC₅₀, in cultured cells derived from two patients with CRPC.</p></div><div><h3>Conclusion</h3><p>The antitumor effects of IM176 were comparable with those of other biguanides. IM176 may therefore be a novel candidate for the treatment of patients with prostate cancer, including those with CRPC.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 2","pages":"Pages 83-90"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/0b/main.PMC10318334.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9803916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of conventional smoking versus electronic cigarette on the expression of VEGF, PEMPA1, and PTEN in rat prostate","authors":"Alireza Namazi Shabestari ,&nbsp;Seyed Saeed Tamehri Zadeh ,&nbsp;Parisa Zahmatkesh ,&nbsp;Leila Zareian Baghdadabad ,&nbsp;Akram Mirzaei ,&nbsp;Rahil Mashhadi ,&nbsp;Gholamreza Mesbah ,&nbsp;Alireza Khajavi ,&nbsp;Milad Akbarzadehmoallemkolaei ,&nbsp;Mahdi Khoshchehreh ,&nbsp;Ramin Rahimnia ,&nbsp;Seyed Mohammad Kazem Aghamir","doi":"10.1016/j.prnil.2022.11.002","DOIUrl":"https://doi.org/10.1016/j.prnil.2022.11.002","url":null,"abstract":"<div><h3>Background</h3><p>The use of electronic cigarettes (e-cigarettes), the alternative to conventional smoking, is increasing considerably worldwide; however, their safety is a matter of debate. Several studies have demonstrated their toxic effects, but no study assessed their effects on the prostate.</p></div><div><h3>Objective</h3><p>The current study aimed at evaluating e-cigarettes and conventional smoking prostate toxicity and effects on the expression of vascular endothelial growth factor A (VEGFA), phosphatase and tensin (PTEN), and prostate transmembrane protein androgen induced 1 (PMEPA1).</p></div><div><h3>Method</h3><p>30 young Wistar rats were categorized into three groups (n = 10) as follows: the control group, the conventional smoking group, and the e-cigarette group. The case groups were exposed to cigarettes or e-cigarettes for 40 minutes, 3 times a day for four months. Serum parameters, prostate pathology, and gene expression were measured at the end of the intervention. Data were analyzed by Graph Pad prism 9.</p></div><div><h3>Results</h3><p>Histopathological findings presented that both types of cigarette-induced hyperemia and induced inflammatory cell infiltration and hypertrophy of smooth muscle of the vascular wall in the e-cigarette group. Expression of <em>PMEPA1,</em> and <em>VEGFA</em> genes significantly increased in conventional (2.67-fold; P = 0.0108, 1.80-fold; P = 0.0461 respectively) and e-cigarettes (1.98-fold; P = 0.0127, 1.34-fold; P = 0.938, respectively) groups compared to the control group. Expression of the <em>PTEN</em> gene non-significantly decreased in the case of groups compared to the control group.</p></div><div><h3>Conclusion</h3><p>We found no significant differences between the two groups in terms of PTEN and PMEPA1 expression, whereas VEGFA was significantly more expressed in a conventional smoking group compared to the e-cigarette group. Therefore, it seems that e-cigarettes could not be taken into account as a better option than conventional smoking, and quitting smoking still is the optimal option.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 2","pages":"Pages 76-82"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50183879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of recurrence sites using 18F-fluorocholine PET/CT in prostate cancer patients with PSA failure","authors":"Dong-Yun Kim ,&nbsp;Won Woo Lee ,&nbsp;Yoo Sung Song ,&nbsp;Sung Kyu Hong ,&nbsp;Seok-Soo Byun ,&nbsp;Jae-Sung Kim","doi":"10.1016/j.prnil.2022.11.001","DOIUrl":"https://doi.org/10.1016/j.prnil.2022.11.001","url":null,"abstract":"<div><h3>Background</h3><p>The optimal condition for the clinical application of ¹⁸F-fluorocholine positron emission tomography–computed tomography (FCH-PET/CT) to detect recurrence sites in prostate-specific antigen (PSA) failure remains unclear due to the heterogeneity of prostate cancer failure. We aimed to evaluate the detection rate of FCH-PET/CT in prostate cancer patients with PSA failure and to determine the optimal PSA level for performing FCH-PET/CT.</p></div><div><h3>Methods</h3><p>FCH-PET/CT was conducted in 89 patients diagnosed with PSA failure after radical treatment (radical prostatectomy in 75 and definitive radiotherapy in 14) between November 2018 and May 2021. Detection rates were examined via receiver operating characteristic (ROC) analysis, and multivariable logistic regression was performed to identify factors affecting positive FCH-PET/CT findings. We also conducted subgroup analyses according to the PSA failure patterns after the radical treatment (persistently high PSA [<em>N</em> = 48] and biochemical recurrence [BCR] [<em>N</em> = 41]).</p></div><div><h3>Results</h3><p>FCH-PET/CT demonstrated a 59.6% overall detection rate, and the optimal PSA threshold for detecting positive findings was ≥ 1.00 ng/mL at the time of imaging. On multivariable analysis, PSA &gt; 1.00 ng/mL (<em>P</em> &lt; 0.001) was a significant predictor of positive FCH-PET/CT findings, especially regarding distant bone metastases (<em>P</em> &lt; 0.001) and recurrence outside the pelvis (<em>P</em> &lt; 0.001). In a subgroup analysis of patients with BCR after initial radical treatment, the area under the ROC curve (AUC) was 0.82, and PSA ≥ 1.75 ng/mL was the optimal value for identifying positive FCH-PET/CT findings. This PSA value was also associated with significantly higher detection rates of distant bone metastases and outside-pelvis metastasis (<em>P</em> &lt; 0.001, both).</p></div><div><h3>Conclusion</h3><p>FCH-PET/CT is a clinically useful tool for detecting tumor recurrence sites in prostate cancer patients with PSA failure if PSA has exceeded a certain value at the time of imaging. Particularly, higher AUC values were observed when FCH-PET/CT was performed in patients with BCR after initial treatment.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 2","pages":"Pages 69-75"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50183880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis","authors":"Hyungwoo Ahn ,&nbsp;Sung Il Hwang ,&nbsp;Hak Jong Lee ,&nbsp;Sang Youn Kim ,&nbsp;Jeong Yeon Cho ,&nbsp;Hakmin Lee ,&nbsp;Sung Kyu Hong ,&nbsp;Seok-Soo Byun ,&nbsp;Taek Min Kim","doi":"10.1016/j.prnil.2022.12.004","DOIUrl":"10.1016/j.prnil.2022.12.004","url":null,"abstract":"<div><h3>Purpose</h3><p>This article aims to evaluate the pooled diagnostic performance control MRI for prediction of recurrent prostate cancer (PCa) after high-intensity focused ultrasound (HIFU).</p></div><div><h3>Materials and methods</h3><p>MEDLINE, EMBASE, and Cochrane library databases up to December 31, 2021, were searched. We included studies providing 2×2 contingency table for diagnostic performance of MRI in predicting recurrent PCa after HIFU, using control biopsy as reference standard. The quality of the included studies was assessed using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Sensitivity and specificity were pooled and displayed in a summary receiver operating characteristics (SROC) plot. Meta-regression analysis using clinically relevant covariates was performed for the causes of heterogeneity.</p></div><div><h3>Results</h3><p>Nineteen studies (703 patients) were included. All included studies satisfied at least four of the seven QUADAS-2 domains. Pooled sensitivity was 0.81 (95% CI 0.72–0.90) with specificity of 0.91 (95% CI 0.86–0.96), with area under the SROC curve of 0.81. Larger studies including more than 50 patients showed relatively poor sensitivity (0.68 vs. 0.84) and specificity (0.75 vs. 0.93). The diagnostic performance of studies reporting higher nadir serum prostate-specific antigen levels (&gt;1 ng/mL) after HIFU was inferior, and differed significantly in sensitivity (0.54 vs. 0.78) rather than specificity (0.85 vs. 0.91).</p></div><div><h3>Conclusions</h3><p>Although MRI showed adequate diagnostic performance in predicting PCa recurrence after HIFU, these results may have been exaggerated.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 2","pages":"Pages 59-68"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/92/main.PMC10318330.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9859856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis","authors":"Yong Nam Gwon,&nbsp;Jae Joon Park,&nbsp;Won Jae Yang,&nbsp;Seung Whan Doo,&nbsp;Jae Heon Kim,&nbsp;Do Kyung Kim","doi":"10.1016/j.prnil.2022.12.002","DOIUrl":"10.1016/j.prnil.2022.12.002","url":null,"abstract":"<div><h3>Background</h3><p>To compare the effects of different alpha-blocker regimes on acute urinary retention (AUR) and the success rate of trial without catheter (TWOC) among patients with AUR secondary to benign prostatic hyperplasia (BPH) to determine the most effective regime.</p></div><div><h3>Methods</h3><p>A comprehensive literature search was performed using PubMed/Medline, Embase, and Cochrane Library up to June 2021. Studies that compared successful TWOC rates between each alpha-blocker regime in patients with AUR secondary to BPH were included. The outcome was the odds ratio of successful TWOC after AUR between groups (each regime of alpha blocker or placebo). To indirectly compare the effect of each alpha-blocker regime on the outcome (successful TWOC rate), a network meta-analysis was conducted using a Bayesian hierarchical random effects model for dichotomous outcomes.</p></div><div><h3>Results</h3><p>In total, 13 randomized controlled trials were included in the present study. There were six nodes (five alpha-blocker regimes and placebo) and eight comparisons in the evidence network plot. Compared to placebo, alfuzosin, silodosin, tamsulosin, and alfuzosin plus tamsulosin resulted in significantly higher TWOC success rates, whereas doxazosin did not show a significant difference in TWOC success rate compared to placebo. Alfuzosin plus tamsulosin was ranked first, followed in order by tamsulosin, silodosin, alfuzosin, and doxazosin. There was no significant inconsistency in the results of this analysis.</p></div><div><h3>Conclusions</h3><p>Alpha blockers may increase the success rate of TWOC. This study evaluated the priority of the effect of several alpha-blocker regimens on AUR related to BPH, which is expected to be helpful in selecting the best medication for patients with AUR.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 2","pages":"Pages 91-99"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/fd/main.PMC10318332.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10180976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates","authors":"Naoya Nagaya ,&nbsp;Kevin J. Chua ,&nbsp;Joshua Sterling ,&nbsp;Shigeo Horie ,&nbsp;Isaac Y. Kim","doi":"10.1016/j.prnil.2022.12.005","DOIUrl":"10.1016/j.prnil.2022.12.005","url":null,"abstract":"<div><h3>Background</h3><p>extended pelvic lymph node dissection (ePLND) increases the detection rate of lymph node positive prostate cancer compared to a standard pelvic lymph node dissection (sPLND). However, improvement of patient outcomes remains questionable. Here we report and compare 3-year postoperative PSA recurrence rates between patients that underwent sPLND versus ePLND at the time of prostatectomy.</p></div><div><h3>Methods</h3><p>162 patients received a sPLND (which involvedremoval of periprostatic, external iliac, and obturator lymph nodes bilaterally), and 142 patients received an ePLND (which involved removal of periprostatic, external iliac, obturator, hypogastric, and common iliac nodes bilaterally). Decision to undergo ePLND versus sPLND at our institution was changed in 2016 based on the National Comprehensive Cancer Network guideline. The median follow-up time was 7 and 3 years for sPLND and ePLND patients, respectively. All node-positive patients were offered adjuvant radiotherapy. Kaplan–Meier analysis was carried out to assess the impact of a PLND on early postoperative PSA progression-free survival. Subgroup analyses were done for node-negative and node-positive patients, as well as Gleason score.</p></div><div><h3>Results</h3><p>Gleason score and T stage were not significantly different between patients who received an ePLND and sPLND. The pN1 rate for ePLND and sPLND were 20% (28/142) and 6% (10/162), respectively. There was no difference in the use of adjuvant treatments in the pN0 patients. Significantly, more ePLND pN1 patients received adjuvant androgen deprivation therapy (25/28 vs. 5/10 <em>P</em> = 0.012) and radiation (27/28 vs. 4/10 <em>P</em> = 0.002). Yet, no difference in biochemical recurrence between ePLND and sPLND was observed (<em>P</em> = 0.44). This remained true in subgroup analyses of node-positive (<em>P</em> = 0.26), node-negative (<em>P</em> = 0.78), Gleason Score 6–7 (<em>P</em> = 0.51), and Gleason Score 8–10 (<em>P</em> = 0.77).</p></div><div><h3>Conclusions</h3><p>PLND provided no additional therapeutic benefit, even though ePLND patients were significantly more likely to have node-positive disease and undergo adjuvant treatment, compared to a sPLND.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 2","pages":"Pages 107-112"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/dd/main.PMC10318318.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9803918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia","authors":"Stephanie S. Kim ,&nbsp;Seung Cho Lee ,&nbsp;Bumjin Lim ,&nbsp;Seung-Ho Shin ,&nbsp;Mee Young Kim ,&nbsp;Sol-Yi Kim ,&nbsp;Hyeyeun Lim ,&nbsp;Clémentine Charton ,&nbsp;Dongho Shin ,&nbsp;Hyong Woo Moon ,&nbsp;Jinho Kim ,&nbsp;Donghyun Park ,&nbsp;Woong-Yang Park ,&nbsp;Ji Youl Lee","doi":"10.1016/j.prnil.2023.01.001","DOIUrl":"10.1016/j.prnil.2023.01.001","url":null,"abstract":"<div><h3>Background</h3><p>DNA methylation markers are considered robust diagnostic features in various cancer types, as epigenetic marks are commonly altered during cancer progression. Differentiation between benign prostatic hyperplasia (BPH) and early-stage prostate cancer (PCa) is clinically difficult, relying on the information of the patient's symptoms or levels of prostate-specific antigen.</p></div><div><h3>Methods</h3><p>A total of 42 PCa patients and 11 BPH patients were recruited. Genomic DNA was purified from tissues and used for the library preparation of the target-enriched methylome with enzymatic conversion and a Twist 85 Mbp EM-seq panel. Paired-end sequencing (150 bp) was performed using NovaSeq 6000 or NextSeq 550. After quality control, including adapter trimming and de-duplication of raw sequencing data, differential methylation patterns were analyzed between the BPH and PCa groups.</p></div><div><h3>Results</h3><p>We report DNA methylation patterns existing between BPH and PCa. The major finding is that broad hypermethylation occurred at genic loci in PCa tissues as compared to the BPH. Gene ontology analysis suggested that hypermethylation of genic loci involved in chromatin and transcriptional regulation is involved in cancer progression. We also compared PCa tissues with high Gleason scores to tissues with low Gleason scores. The high-Gleason PCa tissues showed hundreds of focal differentially methylated CpG sites corresponding to genes functioning in cancer cell proliferation or metastasis. This suggests that dissecting early-to-advanced-grade cancer stages requires an in-depth analysis of differential methylation at the single CpG site level.</p></div><div><h3>Conclusions</h3><p>Our study reports that enzymatic methylome sequencing data can be used to distinguish PCa from BPH and advanced PCa from early-stage PCa. The stage-specific methylation patterns in this study will be valuable resources for diagnostic purposes as well as further development of liquid biopsy approaches for the early detection of PCa.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 2","pages":"Pages 113-121"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/2a/main.PMC10318333.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9859854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current treatment patterns within 1 year after prostate cancer diagnosis in Korean patients over 75 years old: a retrospective multicenter study","authors":"Dong Jin Park ,&nbsp;Ho Won Kang ,&nbsp;Se Yun Kwon ,&nbsp;Young Jin Seo ,&nbsp;Kyung Seop Lee ,&nbsp;Byung Hoon Kim ,&nbsp;Teak Jun Shin ,&nbsp;Won Tae Kim ,&nbsp;Yong-June Kim ,&nbsp;Seok Joong Yun ,&nbsp;Sang-Cheol Lee ,&nbsp;Jae-Wook Chung ,&nbsp;Seock Hwan Choi ,&nbsp;Jun Nyung Lee ,&nbsp;Hyun Tae Kim ,&nbsp;Tae-Hwan Kim ,&nbsp;Eun Sang Yoo ,&nbsp;Tae Gyun Kwon ,&nbsp;Wonho Jung ,&nbsp;Yun-Sok Ha","doi":"10.1016/j.prnil.2022.08.003","DOIUrl":"10.1016/j.prnil.2022.08.003","url":null,"abstract":"<div><h3>Background</h3><p>We aimed to evaluate the current status of first-line treatment options for prostate cancer in patients aged ≥75 years in Korea.</p></div><div><h3>Materials and methods</h3><p>The study included 873 patients diagnosed with biopsy-proven prostate cancer at 5 institutions in Korea from January 2009 to December 2018. Inclusion criteria were aged ≥75 years at diagnosis, prostate biopsy with ≥12 cores, and follow-up period ≥1 year. Clinical data were retrospectively collected from electronic medical records.</p></div><div><h3>Results</h3><p>Primary treatment for prostate cancer in patients aged ≥75 years included androgen deprivation therapy (ADT) (n = 614), radical prostatectomy (RP) (n = 114), and radiation therapy (n = 62). Among patients with RP, nine patients received ADT before RP. The RP group was younger with better Eastern Cooperative Oncology Group Performance Status (ECOG PS), lower initial prostate-specific antigen (PSA), Gleason score (GS), max percent positive cores, less positive cores, and less advanced clinical Tumor Node Metastasis (TNM) stage compared with the ADT group. Multivariate analysis showed that age, ECOG PS, and PSA were independent prognostic factors for RP. When the ADT group was classified by therapeutic regimens, the most common therapeutic regimen was maximal androgen blockade (MAB) (n = 571), and leuprolide + bicalutamide (n = 330) was the most common MAB regimen. Multivariate analysis for secondary treatment showed that age, ECOG PS, GS, and clinical N1 or M1 stage were independent predictive factors. Enzalutamide was the most preferred treatment for tertiary treatment.</p></div><div><h3>Conclusion</h3><p>In patients with prostate cancer aged ≥75 years, the most common treatment option was MAB, and the leuprolide + bicalutamide was the most common MAB regimen. Age, ECOG PS, and PSA are the useful indicators of surgical treatment, which increased during the study period. Younger patients with high GS and advanced clinical stage were more likely to undergo secondary treatment.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"11 1","pages":"Pages 34-39"},"PeriodicalIF":3.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9096969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}